Market Overview:
Blood Urea Nitrogen Diagnostics Market Size Was Valued at USD 1.79 Billion in 2022 and is Projected to Reach USD 2.69 Billion by 2030, Growing at a CAGR of 5.2 % From 2023-2030.
Urea nitrogen is the waste product formed in the liver and removed from the blood by the kidneys. The normal level of urea nitrogen in the blood is 6-24mg/dl. If the level of urea nitrogen is increased than normal, it is a sign that the kidneys aren’t working well. The blood urea nitrogen test is referred to as the BUN diagnostic test which is used to measure the urea nitrogen amount in the blood. Doctors suggest for BUN test as a part of the comprehensive metabolic panel (CMP) or basic metabolic panel (BMP) and this blood-urea nitrogen test is performed when a doctor suspects damage to the kidney. To measure the effectiveness of dialysis treatments like peritoneal dialysis and hemodialysis, the blood urea nitrogen diagnostic test is very useful. This test is also required for the diagnosis of liver damage, malnutrition, poor circulation, dehydration, urinary tract obstruction, congestive heart failure, and gastrointestinal bleeding. Owing to these benefits the blood urea nitrogen diagnostics test supports the market growth over the forecast periods.
Top Key Players Covered in The Blood Urea Nitrogen Diagnostics Market:
- Siemens AG (Germany)
- StressMarq Biosciences Inc (Columbia)
- Thermo Fisher Scientific (US)
- Xpress Bio Life Science (US)
- PerkinElmer, Inc. (US)
- OPTI Medical Systems, Inc. (USA)
- Abbott Laboratories (US)
- F. Hoffmann-La Roche AG (Switzerland)
- Danaher Corporation (US)
- Cutera (USA), and Other Major Players
Market Dynamics and Factors:
The major factor that drives the growth of the blood urea nitrogen diagnostic market. Kidney disease includes Fabry disease, cystinosis, glomerulonephritis, IgA nephropathy, lupus nephritis, atypical hemolytic uremic syndrome, and polycystic kidney disease. The blood urea nitrogen diagnostic test is prescribed when any kidney disease is suspected in people. This test helps to understand if there is any need to carry out dialysis or not. Owing to rising noncommunicable diseases, changing lifestyles, and habits, growing aging population the cases of kidney-diseased patients increased.
The cost associated with the testing equipment is the key factor responsible for restricting the market growth. The prices of the kits, chemical reagents, and other instruments required for the blood urea nitrogen diagnostic test are high. Moreover, to perform the diagnostic test, there is a requirement for extra training for technicians which increases the prices of the diagnostic test. the rising FDA approvals of the diagnostic test and launching of the novel, point-of-care diagnostics tests will provide a lucrative opportunity for the blood urea nitrogen diagnostics market during the forecast periods. Due to the growing prevalence of renal chronic diseases, the manufacturers of the healthcare sector raising their investment in the research and development of new point-of-care tests for diagnosis. For instance, in 2022 Bloom Diagnostic, a manufacturer of medical devices launched a new kidney test product named Bloom kidney test. Additionally, the FDA approvals of such a diagnostic test are also increased. For instance, the FDA approved the blood urea nitrogen point-of-care tests of Siemens Healthineers. Thus, the rising R&D of point-of-care tests and FDA approvals offers a profitable opportunity for the market in the analysis period.
The Blood Urea Nitrogen Diagnostics Market Report Highlight:
- By Test Type, the ELISA test (Enzyme-linked immunosorbent assay) is expected to account for the largest market share in the forecasted period. ELISA is the most ideal test for the detection of urea nitrogen in the blood and it is commonly used in laboratories. The ELISA test has several benefits such as, it has a simple procedure, high specificity, and sensitivity, and high efficiency and cost-effectiveness. Moreover, this test is safe and eco-friendly because there is no requirement for any radioactive substance and a large number of organic solvents.
- By Application, the laboratory segment is predicted to have the maximum market share in blood urea nitrogen diagnostics. The blood urea nitrogen diagnostic test is mostly performed in the laboratory. According to the Centers for Disease Control and Prevention, 70% of the decisions of medical are based on the results of the laboratory, and nearly 14 billion laboratory tests are ordered annually. Statista stated that in 2020 there were 331 million laboratory tests conducted in Russia’s public as well as private organizations.
- By Region, the Asia Pacific region is expected to have the largest market share of the Blood Urea Nitrogen Diagnostics market in the projected period. In this region, the largest population suffers from chronic kidney disease. This is due to the growing prevalence of diabetes. Diabetes is the main cause of chronic kidney disease. For instance, according to Statista, in 2021 there were 206 million people in the western Pacific and 90 million people in Southeast Asia suffering from diabetes.
Key Industry Development:
In November 2023, Thermo Fisher Scientific, a global leader in scientific research and innovation, proudly announces the launch of its latest breakthrough in healthcare technology: a state-of-the-art high-throughput BUN testing platform equipped with advanced automation capabilities.
In October 2023, Siemens AG proudly announced a groundbreaking milestone in healthcare innovation as Siemens Healthiness secured FDA approval for its Atellica IMx BUN assay. This revolutionary advancement introduces a fully automated blood urea nitrogen (BUN) test, marking a significant leap forward in diagnostic efficiency and patient care.
The Blood Urea Nitrogen Diagnostics Market Segmentation:
By Test Type
- ELISA
- Colorimetric
- Spectrophotometric
By Application
- Hospital
- Laboratory
For this report, Introspective Market Research has segmented the Blood Urea Nitrogen Diagnostics Market based on region:
Regional Outlook (Revenue in USD Million; Volume in Units, 2023-2030)
North America
- The U.S.
- Canada
- Mexico
Eastern Europe
- Russia
- Bulgaria
- The Czech Republic
- Hungary
- Poland
- Romania
- Rest of Eastern Europe
Western Europe
- Germany
- UK
- France
- Netherlands
- Italy
- Spain
- Rest of Western Europe
Asia Pacific
- China
- India
- Japan
- Singapore
- Australia
- New-Zealand
- Rest of APAC
Middle East & Africa
- Turkey
- Saudi Arabia
- Qatar
- UAE
- Israel
- South Africa
South America
- Brazil
- Argentina
- Rest of SA
